Pregled bibliografske jedinice broj: 810088
Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis
Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis // Acta diabetologica, 53 (2016), 5; 709-715 doi:10.1007/s00592-016-0861-1 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 810088 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Effectiveness of insulin glargine in type 2
diabetes mellitus patients failing glycaemic
control with premixed insulin: Adriatic countries
data meta-analysis
Autori
Cigrovski Berković, Maja ; Petrovski, Goran ; Grulović, Nataša
Izvornik
Acta diabetologica (0940-5429) 53
(2016), 5;
709-715
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
type 2 diabetes mellitus ; insulin glargine ; premix insulin ; Adriatic
Sažetak
Type 2 diabetes mellitus is a progressive disease, often requiring exogenous insulin therapy and treatment intensification. Despite new therapies, most patients do not reach the recommended HbA1c targets, among them a significant proportion of patients on premixed insulin. Methods: A meta- analysis was carried out in major medical databases up to April 2014, focusing on the Adriatic region. We searched observational studies with duration of at least 6 months, evaluating effectiveness and safety of insulin glargine (IGlar), in combination with OAD or bolus insulin in patients with T2 failing premixed insulin therapy. Outcomes included values of HbA1c, fasting blood glucose, and 2-h postprandial glucose concentration as well as changes in body mass index after at least 6 months of study duration. A meta-analysis was carried out in major medical databases up to April 2014, focusing on Adriatic region. Outcomes included values of HbA1c, fasting blood glucose and 2 h post-prandial glucose concentration as well as changes in body mass index after at least 6 months of study duration. Results: Three prospective, observational, multicentric trials (698 patients in total) were included. The basal-bolus regimen with glargine significantly reduced HbA1c (mean difference, MD 2.27, CI [1.76, 2.78]), fasting glucose (MD 5.15, CI [4.86, 5.44]), and 2-h postprandial glucose concentration (MD 6.94, CI [6.53, 7.34]). No significant changes were found in BMI after switching from premixes to IGlar- based treatment. Conclusion: Insulin glargine- based therapy following premix failure is efficacious and safe option of type 2 diabetes treatment intensification.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-134-1342428-0491 - Neuroendokrini tumori probavnog sustava i gušterače (Cigrovski Berković, Maja, MZOS ) ( CroRIS)
Ustanove:
KBC "Sestre Milosrdnice"
Profili:
Maja Cigrovski Berković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE